The present invention provides a method for manufacturing a microbial detection device, microbial detection method, microbial detection kit and microbial detection device. The manufacturing method includes the following steps: defining a sampling portion and a reaction portion on a substrate. Fiber materials are disposed in the reaction portion and a surface of the reaction portion which contacts with the fiber materials comprises abundant hydroxyl groups. Reaction reagents are then added into the fiber materials. An acidic solution is applied to treat the fiber materials and the hydroxyl groups in the reaction portion.

The present invention relates to methods, monitors and systems, useful, for example, for advanced detection of sepsis in a subject.

The present invention provides a method for manufacturing a microbial detection device, microbial detection method, microbial detection kit and microbial detection device. The manufacturing method includes the following steps: defining a sampling portion and a reaction portion on a substrate. Fiber materials are disposed in the reaction portion and a surface of the reaction portion which contacts with the fiber materials comprises abundant hydroxyl groups. Reaction reagents are then added into the fiber materials. An acidic solution is applied to treat the fiber materials and the hydroxyl groups in the reaction portion.

Devices and methods for sensing analytes in a solution sample are provided. The device includes a substrate, a conversion component configured to convert the analyte in the sample solution into a metabolite, and an aptamer sensor configured to measure a presence of the metabolite, the aptamer sensor located on the substrate.

Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

The present invention relates to a strip for an improved lateral flow assay of a biological sample on a single plane and a lateral flow chromatography assay using a test device containing the same. The strip of the present invention consists of a single-pad, which can improve lateral flow assay by providing an easy and simple procedure and clear visual reading. The strip of the present invention is consisted of sample application (sample) zone and reactant-resultant zone where the reaction mixture is deposited (reactant) are all on a same plane. In addition, the present invention provides a chromatographic method wherein hemoglobin is separated from analyte by a differential chromatography on the solid phase. Any interference of detection of the result by hemoglobin is removed by the present invention. The present invention provides advantages including an easy and simple procedure with a quick and clear response.

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.

The present disclosure provides a method of determining treatment for cancer comprising identifying the absence of malic enzyme 1 (ME1) and treating with an inducer of ferroptosis.